ALVO logo

Alvotech (ALVO)

$4.27

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ALVO

Market cap

$1.33B

EPS

0.1

P/E ratio

--

Price to sales

2.11

Dividend yield

--

Beta

0.051768

Price on ALVO

Previous close

$3.99

Today's open

$3.89

Day's range

$3.75 - $4.37

52 week range

$2.94 - $9.25

Profile about ALVO

CEO

Lisa Graver

Employees

1032

Headquarters

Luxembourg, LU

Exchange

NASDAQ Global Market

Shares outstanding

312153164

Issue type

Common Stock

ALVO industries and sectors

Healthcare

Pharmaceuticals

News on ALVO

Alvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian Markets

REYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech's candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab).

news source

GlobeNewsWire • 21 hours ago

news preview

Alvotech Q2 Earnings Call Highlights

Alvotech NASDAQ: ALVO said its first-half 2026 results reflected a temporary manufacturing slowdown tied to facility and quality-system improvements at its Reykjavik site, while management reaffirmed full-year revenue and adjusted EBITDA guidance and highlighted upcoming regulatory decisions and product launches.

news source

MarketBeat • Aug 20, 2026

news preview

Alvotech (ALVO) Q2 2026 Earnings Call Transcript

Alvotech (ALVO) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 20, 2026

news preview

Alvotech: Reiterate Hold On AVT05/AVT06 BLA Resubmissions And Upcoming Catalysts

Alvotech maintains at a Hold rating due to missed H1 2026 earnings and ongoing regulatory challenges, despite pipeline progress. Recent FDA CRLs for AVT05 and AVT06 were due to manufacturing issues, now addressed, with BLAs resubmitted and multiple approvals targeted for Q4 2026. AVT06, a biosimilar to EYLEA, has global commercialization rights secured post-November 2026, with patent disputes resolved and a large market opportunity.

news source

Seeking Alpha • Aug 20, 2026

news preview

Alvotech Announces Financial Results for the First Half of 2026 and Provides a Business Update

REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update.

news source

GlobeNewsWire • Aug 19, 2026

news preview

Alvotech (ALVO) Reports Q2 Loss, Beats Revenue Estimates

Alvotech (ALVO) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to earnings of $0.14 per share a year ago.

news source

Zacks Investment Research • Aug 19, 2026

news preview

Alvotech to Report Financial Results for H1 2026

REYKJAVIK,  ICELAND (August 10, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, August 20, 2026, at 08:00 ET (12:00 GMT, 13:00 BST, 14:00 CEST).

news source

GlobeNewsWire • Aug 10, 2026

news preview

Alvotech announces successful closure of FDA inspection of manufacturing facility

REYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has closed its inspection of the company's manufacturing facility in Reykjavik, Iceland, conducted in May 2026. The FDA has confirmed the inspection classification of the manufacturing site is Voluntary Action Indicated (VAI).

news source

GlobeNewsWire • Jul 29, 2026

news preview

Transactions of Managers and Closely Associated Persons

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons, announcing the pledging of (i) 88,940,619 shares and (ii) 7,007,321 depository receipts on shares in Alvotech by Celtic Lux Holdings S.a. r.l. (formerly known as Alvogen Lux Holdings S.a. r.l.). The date of the transactions was June 26, 2026.

news source

GlobeNewsWire • Jul 3, 2026

news preview

Alvotech further strengthens liquidity by securing term loan facility of $75 million

REYKJAVIK, ICELAND (July 1, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has amended its existing credit agreement with funds managed by GoldenTree Asset Management LP and other existing lenders of Alvotech to provide a term loan facility of up to $75 million in additional capital.

news source

GlobeNewsWire • Jul 1, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Alvotech

Open an M1 investment account to buy and sell Alvotech commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ALVO on M1